Placebo-containing MNA

DRUG2 trials

Sponsors

SkinJect, Inc.

Conditions

Basal Cell Carcinoma

Phase 1

Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)

TerminatedNCT03646188

SkinJect, Inc.Basal Cell Carcinoma

Start: 2020-06-10End: 2021-05-04Updated: 2026-04-16

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

Active, not recruitingNCT04928222

SkinJect, Inc.Basal Cell Carcinoma

Start: 2021-09-24End: 2024-06-30Target: 25Updated: 2023-04-14